placenta-derived multipotent mesenchymal stromal cells (Institute of Cell Therapy)

This cell-based therapy, developed by the Institute of Cell Therapy in Ukraine, consists of cryopreserved allogeneic multipotent mesenchymal stromal cells (MMSCs) derived from human placenta and umbilical cord. Designed as a biologic treatment for COVID-19 pneumonia and associated acute respiratory distress syndrome (ARDS), the therapy leverages the regenerative and immunomodulatory properties of mesenchymal stem cells. The mechanism of action involves the reduction of systemic inflammation and lung fibrosis through immunosuppressant effects, alongside the promotion of damaged lung tissue repair. A key safety feature of these P-MMSCs is their lack of ACE-2 receptors, which makes the therapeutic cells resistant to direct infection by the SARS-CoV-2 virus. Each preparation typically contains approximately 70 million cells, intended for intravenous infusion.

Other names

Cryopreserved allogeneic multipotent mesenchymal stem cells of the placenta and umbilical cordPlacenta-Derived MMSCsCryopreserved Placenta-Derived Multipotent Mesenchymal Stromal Cells